Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2020-08-31 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
2020年第四次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening and procedures of the 2020 fourth extraordinary general meeting of shareholders of Yunnan Watson Biotechnology Co., Ltd. It details the legality of the meeting's notice, attendance, voting procedures, and the validity of the resolutions passed. It does not contain financial statements or results but focuses on the legal compliance and procedural correctness of the shareholder meeting. This type of document is typically classified as Declaration of Voting Results & Voting Rights Announcements (DVA) because it reports on the official voting results and validates the shareholder meeting process.
2020-08-31 Chinese
2020年第四次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2020 fourth extraordinary general meeting of shareholders of Yunnan Watson Biotechnology Co., Ltd. It includes information about the meeting date, attendance, voting methods, voting results on specific proposals, and legal opinions confirming the validity of the meeting and resolutions. The document does not contain financial statements or detailed financial performance data, but rather the official voting results and decisions made at the shareholders' meeting. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 2428 characters, which is consistent with a detailed voting results announcement rather than a full report or presentation. Therefore, the correct classification is DVA with high confidence.
2020-08-31 Chinese
关于召开2020年第四次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement about the convening of the 2020 fourth extraordinary general meeting of shareholders for Yunnan Watson Biotechnology Co., Ltd. It includes information about the meeting date, voting procedures, proposals to be discussed, registration details, and attachments such as proxy forms and voting instructions. The document does not contain financial statements or results but serves as a notice and procedural guide for the shareholders' meeting. It is not a report of voting results, nor is it a presentation or financial report. Given the content and length (4321 characters), it fits the category of a Proxy Solicitation & Information Statement, which provides information and requests votes for meetings.
2020-08-25 Chinese
关于2018年股票期权激励计划首次授予股票期权第一个行权期采用自主行权模式的提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the first exercise period of a 2018 stock option incentive plan by Yunnan Watson Biotechnology Co., Ltd. It includes specifics about the stock options granted, exercise conditions, exercise period, pricing, and the impact on the company. The document is a formal announcement about the stock option exercise event and its terms, not a financial report or audit. It does not contain financial statements or quarterly/annual results but focuses on stock option exercise details and compliance with regulatory requirements. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about stock option exercise conditions and procedures, not a full report or earnings release.
2020-08-25 Chinese
关于2018年股票期权激励计划部分已授予股票期权注销完成的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement regarding the cancellation of certain stock options granted under the company's 2018 stock option incentive plan. It details the board meeting decisions, the number of stock options cancelled, and confirmation of completion by the securities registration authority. The content focuses on changes in stock option grants due to personnel changes and regulatory compliance. This fits the category of a Transaction in Own Shares (POS), as it involves the cancellation (a form of share capital adjustment) of stock options previously granted by the company. The document is short and specific to this transaction, not a full financial report or other type of filing.
2020-08-19 Chinese
关于归还部分用于暂时补充流动资金的闲置募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is a company announcement regarding the return of idle raised funds temporarily used to supplement working capital. It details the amounts, dates, and board approvals related to the use and return of these funds. There is no financial statement, audit, or detailed report content. The document is short (795 characters) and serves as a formal notification of a capital/financing update related to the use and return of raised funds. This fits the Capital/Financing Update (CAP) category rather than a full financial report or regulatory filing.
2020-08-14 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.